Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-08-09

Clinical Trial Update: Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating oral lucerastat as monotherapy in adults with Fabry disease; results assessing efficacy and safety have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lucerastat (lucerastat)

Snippet

Sponsor: Idorsia Pharmaceuticals Ltd. | Conditions: Fabry Disease | Phase 3 | Status: COMPLETED | Results posted: 2024-08-09